Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00 at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised its price target on Mirum Pharmaceuticals to $130 (from $125) and maintained a "buy" rating, implying about a 36.33% upside from the current share price.
• Mirum's latest quarter showed strong top-line momentum with revenue up 49.8% year‑over‑year, but it missed on EPS (reported -$0.11 vs. $0.02 est.) and analysts still expect negative full‑year earnings.
• Analyst sentiment is mixed but generally positive (consensus "Moderate Buy" with an average target of $121.75), while insiders have sold roughly 89,513 shares (~$8.38M) in the last 90 days even as major institutions materially increased holdings.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) had its target price upped by investment analysts at Stifel Nicolaus from $125.00 to $130.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' price objective would suggest a potential upside of 36.33% from the stock's current price.

A number of other analysts have also recently issued reports on MIRM. Leerink Partners decreased their target price on Mirum Pharmaceuticals from $120.00 to $118.00 and set an "outperform" rating for the company in a research report on Thursday, February 26th. Citizens Jmp reaffirmed a "market outperform" rating and issued a $132.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Evercore set a $126.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, March 4th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $121.75.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $95.36 on Wednesday. Mirum Pharmaceuticals has a 12 month low of $40.00 and a 12 month high of $109.28. The firm has a market capitalization of $5.81 billion, a P/E ratio of -198.46 and a beta of 0.51. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The company's fifty day moving average price is $94.16 and its 200 day moving average price is $85.07.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business's revenue was up 49.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.00 EPS. As a group, sell-side analysts predict that Mirum Pharmaceuticals will post -1.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Joanne Quan sold 7,287 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider directly owned 18,864 shares in the company, valued at $1,735,110.72. This trade represents a 27.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jolanda Howe sold 4,732 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the transaction, the senior vice president owned 8,429 shares in the company, valued at approximately $775,299.42. This trade represents a 35.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 89,513 shares of company stock worth $8,377,249. 22.87% of the stock is currently owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently made changes to their positions in MIRM. Janus Henderson Group PLC boosted its holdings in shares of Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock valued at $479,050,000 after acquiring an additional 1,067,722 shares in the last quarter. State Street Corp lifted its position in Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company's stock valued at $169,354,000 after purchasing an additional 797,088 shares during the period. Wellington Management Group LLP lifted its position in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company's stock valued at $44,889,000 after purchasing an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its position in Mirum Pharmaceuticals by 2,116.6% during the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company's stock worth $28,560,000 after purchasing an additional 371,999 shares during the period.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Robert W. Baird raised its price target on MIRM from $95 to $112 and kept an "outperform" rating — a near‑term bullish catalyst that supports upside expectations. Baird raise
• Neutral Sentiment: Recent quarterly results showed revenue growth (year‑over‑year increase ~50%) but an EPS miss; consensus still expects FY2026 losses. Investors should weigh top‑line momentum against continuing negative profitability. Company financials
• Negative Sentiment: HC Wainwright cut EPS forecasts across 2026 (Q1 to ($0.26) from ($0.18); Q2 to ($0.20) from ($0.17); Q3 to ($0.18) from ($0.14); Q4 to $0.04 from $0.06) and lowered FY2026 from ($0.41) to ($0.58). These downward revisions pressure near‑term earnings expectations and could weigh on sentiment despite the firm's maintained "Buy" rating and $150 target. HC Wainwright notes

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.